GlassScriptPhysician profile
Sheetal Shroff
NPI 1619270576
$139,678.60
in general payments reported to CMS, 2019-2025
29 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $2,809 · 2021: $1,709 · 2022: $10K · 2023: $21K · 2024: $62K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Consulting Fee: $20K · Travel and Lodging: $8,008 · Food and Beverage: $4,653 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,563.00 |
| Consulting Fee | $19,865.00 |
| Travel and Lodging | $8,007.52 |
| Food and Beverage | $4,652.53 |
| Education | $263.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $49,263.15 | 2023-2025 | Rystiggo, Zilbrysq, Briviact |
| Alnylam Pharmaceuticals INC. | $33,850.44 | 2020-2025 | Amvuttra, Onpattro |
| Argenx US, INC. | $33,176.72 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $18,791.71 | 2024-2025 | Wainua |
| Alexion Pharmaceuticals, INC. | $1,652.33 | 2019-2025 | Ultomiris |
| Ucb Sa | $1,186.29 | 2019 | |
| Avanir Pharmaceuticals, INC. | $406.52 | 2019-2022 | |
| Biogen, INC. | $323.88 | 2019-2025 | Spinraza, Vumerity, Tysabri |
| Tanabe Pharma America, INC. | $176.33 | 2021-2025 | Radicava |
| Hospira, INC. | $126.21 | 2024-2025 | |
| Akcea Therapeutics, INC. | $107.73 | 2019 | |
| Pfizer INC. | $99.65 | 2023-2025 | |
| Horizon Therapeutics Plc | $79.04 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.67 | 2024-2025 | Hyqvia |
| Catalyst Pharmaceuticals, INC. | $62.09 | 2020-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $44.97 | 2025 | |
| Merz North America, INC. | $36.91 | 2019 | |
| Emd Serono, INC. | $30.25 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $28.67 | 2023 | Relyvrio |
| Acorda Therapeutics, INC | $24.26 | 2019 | |
| Acadia Pharmaceuticals INC | $22.52 | 2025 | Nuplazid |
| Csl Behring | $21.93 | 2025 | Hizentra |
| Eisai INC. | $20.93 | 2025 | |
| Genzyme Corporation | $19.22 | 2019 | |
| Strongbridge US INC. | $17.10 | 2020 | |
| Grt US Holding, INC. | $17.08 | 2020 | |
| Abbvie INC. | $15.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Shroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.